

# Pranita Tamma

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4379757/publications.pdf>

Version: 2024-02-01

42  
papers

2,412  
citations

394421

19  
h-index

276875

41  
g-index

42  
all docs

42  
docs citations

42  
times ranked

3402  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination Therapy for Treatment of Infections with Gram-Negative Bacteria. <i>Clinical Microbiology Reviews</i> , 2012, 25, 450-470.	13.6	617
2	Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant <i>Enterobacteriaceae</i> Bacteremia. <i>Clinical Infectious Diseases</i> , 2017, 64, 257-264.	5.8	286
3	Safety of influenza vaccination during pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 201, 547-552.	1.3	250
4	Considerations for the Use of Phage Therapy in Clinical Practice. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0207121.	3.2	151
5	The Use of Cefepime for Treating AmpC $\beta$ -Lactamase-Producing <i>Enterobacteriaceae</i> . <i>Clinical Infectious Diseases</i> , 2013, 57, 781-788.	5.8	136
6	Comparing the Outcomes of Adults With <i>Enterobacteriaceae</i> Bacteremia Receiving Short-Course Versus Prolonged-Course Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohort. <i>Clinical Infectious Diseases</i> , 2018, 66, 172-177.	5.8	131
7	Chlorhexidine Use in the Neonatal Intensive Care Unit: Results from a National Survey. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 846-849.	1.8	95
8	Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 34-48.	1.3	85
9	Ventilator-Associated Tracheitis in Children: Does Antibiotic Duration Matter?. <i>Clinical Infectious Diseases</i> , 2011, 52, 1324-1331.	5.8	60
10	Antibiotic Therapy for <i>Pseudomonas aeruginosa</i> Bloodstream Infections: How Long Is Long Enough?. <i>Clinical Infectious Diseases</i> , 2019, 69, 2011-2014.	5.8	60
11	Defining the Role of Novel $\beta$ -Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 251-260.	1.3	53
12	Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance. <i>Clinical Infectious Diseases</i> , 2021, 73, e4599-e4606.	5.8	39
13	Cefiderocol Activity Against Clinical <i>Pseudomonas aeruginosa</i> Isolates Exhibiting Ceftolozane-Tazobactam Resistance. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab311.	0.9	39
14	An Outbreak of Extended-Spectrum $\beta$ -Lactamase-Producing <i>Klebsiella pneumoniae</i> in a Neonatal Intensive Care Unit. <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 631-634.	1.8	32
15	Determining the Optimal Carbapenem MIC That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6425-6429.	3.2	32
16	Empiric Combination Therapy for Gram-Negative Bacteremia. <i>Pediatrics</i> , 2014, 133, e1148-e1155.	2.1	30
17	Does the Piperacillin Minimum Inhibitory Concentration for <i>Pseudomonas aeruginosa</i> Influence Clinical Outcomes of Children With Pseudomonas Bacteremia?. <i>Clinical Infectious Diseases</i> , 2012, 55, 799-806.	5.8	29
18	The Association of Antibiotic Duration With Successful Treatment of Community-Acquired Pneumonia in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 267-273.	1.3	29

#	ARTICLE	IF	CITATIONS
19	Policy Statement: Antibiotic Stewardship in Pediatrics. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 641-649.	1.3	28
20	A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis. <i>American Journal of Medicine</i> , 2017, 130, 842-845.	1.5	21
21	Can Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF) Enhance Antimicrobial Stewardship Efforts in the Acute Care Setting?. <i>Infection Control and Hospital Epidemiology</i> , 2013, 34, 990-995.	1.8	20
22	Determining the Optimal Ceftriaxone MIC for Triggering Extended-Spectrum $\beta$ -Lactamase Confirmatory Testing. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2228-2230.	3.9	20
23	Prevalence of <i>bla</i> CTX-M Genes in Gram-Negative Bloodstream Isolates across 66 Hospitals in the United States. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	20
24	Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere <i>Clostridioides difficile</i> Infections. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz492.	0.9	19
25	Antibiotic-Associated Adverse Events in Hospitalized Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 622-628.	1.3	19
26	Antibiotic Susceptibility of Common Pediatric Uropathogens in the United States. <i>Clinical Infectious Diseases</i> , 2014, 59, 750-752.	5.8	18
27	PRO: Testing for ESBL production is necessary for ceftriaxone-non-susceptible Enterobacterales: perfect should not be the enemy of progress. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab019.	2.1	18
28	Using Patient Risk Factors to Identify Whether Carbapenem-Resistant Enterobacteriaceae Infections Are Caused by Carbapenemase-Producing Organisms. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy094.	0.9	15
29	Consensus on $\beta$ -Lactamase Nomenclature. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0033322.	3.2	11
30	Combination of phage therapy and cefiderocol to successfully treat <i>Pseudomonas aeruginosa</i> cranial osteomyelitis. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac046.	2.1	11
31	Behavior Outbursts, Orofacial Dyskinesias, and CSF Pleocytosis in a Healthy Child. <i>Pediatrics</i> , 2011, 128, e242-e245.	2.1	7
32	Navigating treatment approaches for presumed ESBL-producing infections. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlaa111.	2.1	7
33	Antibacterial Resistance Leadership Group 2.0: Back to Business. <i>Clinical Infectious Diseases</i> , 2021, 73, 730-739.	5.8	7
34	Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications. <i>Paediatric Drugs</i> , 2016, 18, 1-11.	3.1	4
35	Engaging Patients and Caregivers in a Transdisciplinary Effort to Improve Outpatient Parenteral Antimicrobial Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa188.	0.9	3
36	Survey of infectious diseases providers reveals variability in duration of antibiotic therapy for the treatment of Gram-negative bloodstream infections. <i>JAC-Antimicrobial Resistance</i> , 2021, 4, dlac005.	2.1	3

#	ARTICLE	IF	CITATIONS
37	Preface. Infectious Disease Clinics of North America, 2014, 28, xi-xii.	5.1	2
38	Phage Are All the Rage: Bacteriophage in Clinical Practice. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 749-753.	1.3	2
39	Reply to Al-Hasan et al. Clinical Infectious Diseases, 2018, 66, 1979-1981.	5.8	1
40	Reply to Chou and Trautner. Clinical Infectious Diseases, 2018, 67, 483-483.	5.8	1
41	Disk Correlates for Revised Clinical and Laboratory Standards Institute <i>Enterobacterales</i> Piperacillin-Tazobactam MIC Breakpoints. Journal of Clinical Microbiology, 2022, , e0024322.	3.9	1
42	Reply to Wang and Lai, and to Woerther et al. Clinical Infectious Diseases, 2020, 71, 2540-2541.	5.8	0